Literature DB >> 33197400

Institutional-Level Differences in Quality and Outcomes of Lung Cancer Resections in the United States.

Raymond U Osarogiagbon1, Helmneh M Sineshaw2, Chun Chieh Lin2, Ahmedin Jemal2.   

Abstract

BACKGROUND: Institutional-level disparities in non-small cell lung cancer (NSCLC) survival may be driven by reversible differences in care-delivery processes. We quantified the impact of differences in readily identifiable quality metrics on long-term survival disparities in resected NSCLC. RESEARCH QUESTION: How do reversible differences in oncologic quality of care contribute to institutional-level disparities in early-stage NSCLC survival? STUDY DESIGN AND METHODS: We retrospectively analyzed patients in the National Cancer Data Base who underwent NSCLC resection from 2004 through 2015 within institutions categorized as Community, Comprehensive Community, Integrated Network, Academic, and National Cancer Institute (NCI)-Designated Cancer Programs. We estimated percentages and adjusted ORs for six potentially avoidable poor-quality markers: incomplete resection, nonexamination of lymph nodes, nonanatomic resection, non-evidence-based use of adjuvant chemotherapy, non-evidence-based use of adjuvant radiation therapy, and 60-day postoperative mortality. By sequentially eliminating patients with poor-quality markers and calculating adjusted hazard ratios, we quantified their overall survival impact.
RESULTS: Of 169,775 patients, 7%, 46%, 10%, 24%, and 12% underwent surgery at Community, Comprehensive Community, Integrated Network, Academic, and NCI-Designated Cancer Programs, with 5-year overall survival rates of 52%, 56%, 58%, 60% and 66%, respectively. After the sequential elimination process, using NCI-Designated Cancer Centers as a reference, the adjusted hazard ratio for 5-year overall survival changed from 1.47 (95% CI, 1.41-1.53), 1.29 (95% CI, 1.25-1.33), 1.18 (95% CI, 1.14-1.23), and 1.20 (95% CI, 1.16-1.24) for Community, Comprehensive Community, Integrated Networks, and Academic Cancer Programs to 1.35 (95% CI, 1.28-1.42), 1.22 (95% CI, 1.17-1.26), 1.16 (95% CI, 1.11-1.22), and 1.17 (95% CI, 1.12-1.21), respectively (P < .001 for all comparisons with NCI-designated programs). Differences in quality of surgical resection and postoperative care accounted for 11% to 26% of the interinstitutional survival disparities.
INTERPRETATION: Targeting six readily identified poor-quality markers narrowed, but did not eliminate, institutional survival disparities. The greatest impact was in community programs. Residual factors driving persistent institution-level long-term NSCLC survival disparities must be characterized to eliminate them.
Copyright © 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  health-care disparities; lung cancer surgery; non-small cell lung cancer; quality improvement

Mesh:

Year:  2020        PMID: 33197400      PMCID: PMC8147100          DOI: 10.1016/j.chest.2020.10.075

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  56 in total

1.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

Authors:  Mark G Kris; Bruce E Johnson; Lynne D Berry; David J Kwiatkowski; A John Iafrate; Ignacio I Wistuba; Marileila Varella-Garcia; Wilbur A Franklin; Samuel L Aronson; Pei-Fang Su; Yu Shyr; D Ross Camidge; Lecia V Sequist; Bonnie S Glisson; Fadlo R Khuri; Edward B Garon; William Pao; Charles Rudin; Joan Schiller; Eric B Haura; Mark Socinski; Keisuke Shirai; Heidi Chen; Giuseppe Giaccone; Marc Ladanyi; Kelly Kugler; John D Minna; Paul A Bunn
Journal:  JAMA       Date:  2014-05-21       Impact factor: 56.272

2.  Survival impact of postoperative therapy modalities according to margin status in non-small cell lung cancer patients in the United States.

Authors:  Matthew P Smeltzer; Chun Chieh Lin; Feng-Ming Spring Kong; Ahmedin Jemal; Raymond U Osarogiagbon
Journal:  J Thorac Cardiovasc Surg       Date:  2017-04-04       Impact factor: 5.209

3.  Rurality, Stage-Stratified Use of Treatment Modalities, and Survival of Non-small Cell Lung Cancer.

Authors:  Meredith A Ray; Nicholas R Faris; Anna Derrick; Matthew P Smeltzer; Raymond U Osarogiagbon
Journal:  Chest       Date:  2020-05-06       Impact factor: 9.410

4.  Invasive mediastinal staging for resected non-small cell lung cancer in a population-based cohort.

Authors:  Raymond U Osarogiagbon; Yu-Sheng Lee; Nicholas R Faris; Meredith A Ray; Philip O Ojeabulu; Matthew P Smeltzer
Journal:  J Thorac Cardiovasc Surg       Date:  2019-05-02       Impact factor: 5.209

5.  Trends and Patterns of Disparities in Cancer Mortality Among US Counties, 1980-2014.

Authors:  Ali H Mokdad; Laura Dwyer-Lindgren; Christina Fitzmaurice; Rebecca W Stubbs; Amelia Bertozzi-Villa; Chloe Morozoff; Raghid Charara; Christine Allen; Mohsen Naghavi; Christopher J L Murray
Journal:  JAMA       Date:  2017-01-24       Impact factor: 56.272

Review 6.  Postoperative radiotherapy for non-small cell lung cancer.

Authors:  Sarah Burdett; Larysa Rydzewska; Jayne Tierney; David Fisher; Mahesh Kb Parmar; Rodrigo Arriagada; Jean Pierre Pignon; Cecile Le Pechoux
Journal:  Cochrane Database Syst Rev       Date:  2016-10-11

7.  Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base.

Authors:  Karl Y Bilimoria; David J Bentrem; Andrew K Stewart; David P Winchester; Clifford Y Ko
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

8.  Number of lymph nodes associated with maximal reduction of long-term mortality risk in pathologic node-negative non-small cell lung cancer.

Authors:  Raymond U Osarogiagbon; Obiageli Ogbata; Xinhua Yu
Journal:  Ann Thorac Surg       Date:  2013-11-20       Impact factor: 4.330

9.  Volume-Based Care Regionalization: Pitfalls and Challenges.

Authors:  Raymond U Osarogiagbon
Journal:  J Clin Oncol       Date:  2020-09-08       Impact factor: 50.717

10.  Geographic Distribution and Survival Outcomes for Rural Patients With Cancer Treated in Clinical Trials.

Authors:  Joseph M Unger; Anna Moseley; Banu Symington; Mariana Chavez-MacGregor; Scott D Ramsey; Dawn L Hershman
Journal:  JAMA Netw Open       Date:  2018-08-03
View more
  2 in total

1.  Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216).

Authors:  Kenneth L Kehl; David Zahrieh; Ping Yang; Shauna L Hillman; Angelina D Tan; Jacob M Sands; Geoffrey R Oxnard; Erin A Gillaspie; Dennis Wigle; Shakun Malik; Thomas E Stinchcombe; Suresh S Ramalingam; Karen Kelly; Ramaswamy Govindan; Sumithra J Mandrekar; Raymond U Osarogiagbon; David Kozono
Journal:  JAMA Oncol       Date:  2022-05-01       Impact factor: 33.006

2.  Outcomes After Use of a Lymph Node Collection Kit for Lung Cancer Surgery: A Pragmatic, Population-Based, Multi-Institutional, Staggered Implementation Study.

Authors:  Raymond U Osarogiagbon; Matthew P Smeltzer; Nicholas R Faris; Meredith A Ray; Carrie Fehnel; Phillip Ojeabulu; Olawale Akinbobola; Meghan Meadows-Taylor; Laura M McHugh; Ahmed M Halal; Paul Levy; Vishal Sachdev; David Talton; Lynn Wiggins; Xiao-Ou Shu; Yu Shyr; Edward T Robbins; Lisa M Klesges
Journal:  J Thorac Oncol       Date:  2021-02-16       Impact factor: 15.609

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.